Results 211 to 220 of about 87,351 (255)
Some of the next articles are maybe not open access.
Alpha1-Antitrypsin Augmentation Therapy
1993Alpha 1-proteinase inhibitor (also known as alpha 1-antitrypsin) derived from pooled human serum (Prolastin, Miles Biologicals) has been available in the United States since 1988. Although no formal controlled prospective study has been performed to prove its efficacy, intravenous administration of Prolastin has been the accepted treatment for ...
openaire +2 more sources
Pindolol Augmentation of Antidepressant Therapy
The Australian Journal of Hospital Pharmacy, 1999To review the safety and efficacy of pindolol in augmenting the response to antidepressant drugs.
Christopher P Alderman, Tania Colarco
openaire +1 more source
Adenosine Augmentation Therapy
2012Abstract The ribonucleoside adenosine is based on the purine base adenine, which was most likely already present on the prebiotic primitive Earth.1 Being the core molecule of the energy metabolite adenosine-5′-triphosphate (ATP) as well as being an integral component of both DNA and RNA, adenosine likely played an important role in early
openaire +1 more source
Error-augmented bimanual therapy for stroke survivors
NeuroRehabilitation, 2018BACKGROUND: Stroke recovery studies have shown the efficacy of bimanual training on upper limb functional recovery and others have shown the efficacy of feedback technology that augments error. OBJECTIVE: In a double-blinded randomized controlled study (N = 26), we evaluated the short-term effects of bilateral arm training to foster functional recovery
Farnaz, Abdollahi +4 more
openaire +3 more sources
Acamprosate Calcium as Augmentation Therapy for Anxiety Disorders
Annals of Pharmacotherapy, 2010Background: Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate calcium is thought to restore this chemical
Thomas L, Schwartz +3 more
openaire +2 more sources
Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets, 2013SERPINA1, α-antitrypsin (AAT) is an acute phase protein, a member of the serpin (serine protease inhibitor) super family and one of the most abundant protease inhibitors in the circulation. The clinical importance of AAT is emphasized in persons with inherited AAT deficiency who exhibit high risk of developing early onset pulmonary emphysema, neonatal ...
Janciauskiene, Sabina, Welte, Tobias
openaire +2 more sources
Augmentation of Electroconvulsive Therapy Seizures With Sleep Deprivation
The Journal of ECT, 2004Electroconvulsive therapy (ECT) is the fastest and most effective treatment for severe or treatment-resistant affective and psychotic disorders. Its therapeutic effect is obtained through a generalized tonic-clonic seizure of adequate duration. Several factors (older age, male gender, and the sessions of ECT themselves) increase seizure threshold and ...
Ester, Gilabert +2 more
openaire +2 more sources
Augmenting Agents in Cancer Therapy
JAMA: The Journal of the American Medical Association, 1981The title of this book implies that there are chemicals or biologic materials, augmenting agents, that work by enhancing the activity of other forms of therapy rather than through any direct effect themselves. In fact, the volume is an encyclopedia of many disparate kinds of natural or synthetic products that work directly or through the immune system ...
openaire +1 more source
Sensor-Augmented Pump Therapy at 36 Months
Diabetes Technology & Therapeutics, 2012Background: This follow-up study investigates the metabolic and psychosocial effects of sensor-augmented pump (SAP) therapy in adults with type 1 diabetes 36 months after therapy start. Subjects and Methods: We invited all 24 Danish ...
Schmidt, Signe, Nørgaard, Kirsten
openaire +3 more sources
Augmentation therapy in α-1 antitrypsin deficiency
Expert Opinion on Biological Therapy, 2008Alpha-1 antitrypsin deficiency is a genetic disorder that leads to early-onset emphysema. Recently, exogenous supplementation of the enzyme has become a therapeutic alternative.To review the role of so-called augmentation therapy with pooled human plasma alpha-1 antitrypsin as a specific treatment for emphysema caused by alpha-1 antitrypsin deficiency ...
Gustavo A, Heresi, James K, Stoller
openaire +2 more sources